Back

BioMarin gets $97 price target after positive VOXZOGO Phase 3 results

Verifying
  • BioMarin Pharmaceutical received a $97 price-target upgrade from BMO Capital.
  • The revised target represents about 50% upside from current levels.
  • VOXZOGO Phase 3 results showed significant growth in hypochondroplasia treatment research.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.